Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00621192
Other study ID # HHSN267200700051C
Secondary ID HHSN267200700051
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date June 2008
Est. completion date October 2009

Study information

Verified date March 2023
Source The Emmes Company, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Meropenem is an antibiotic that is commonly used to treat serious infections. Although it is used in premature and young infants, the correct dose is not known. The purpose of this study is to determine the correct dose and the safety of meropenem for the treatment of complicated intra-abdominal infections in these young babies.


Description:

This study will evaluate the safety, tolerability and Pharmacokinetics - Pharmacodynamics (PK-PD) of meropenem in infants <91 days of age with suspected and complicated intra-abdominal infections. The specific aims of this trial are: 1. To characterize meropenem single-dose and multiple-dose PK in subjects with suspected and complicated intra-abdominal infections. 2. To characterize the safety profile of meropenem in the treatment of suspected and complicated intra-abdominal infections. 3. To assess collected efficacy data for meropenem for the treatment of suspected and complicated intra-abdominal infections.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date October 2009
Est. primary completion date October 2009
Accepts healthy volunteers No
Gender All
Age group N/A to 90 Days
Eligibility Inclusion Criteria: 1. Written permission from parent or legal guardian 2. Age younger than 91 days 3. Likely to survive beyond the first 48 hours after enrollment 4. Sufficient intravascular access (either peripheral or central) to receive study drug. AND ONE OF THE FOLLOWING 5. 1) Physical, radiological, and/or bacteriological findings of a complicated intra-abdominal infection. These include peritonitis, NEC (Necrotizing Enterocolitis) Grade II or higher by Bell's criteria, Hirschsprung's disease with perforation, spontaneous perforation, meconium ileus with perforation, bowel obstruction with perforation, as evidenced by free peritoneal air on abdominal radiograph, intestinal pneumatosis or portal venous gas on abdominal radiographic examination. OR 2) Possible NEC OR 3) Otherwise receiving meropenem per local standard of care Exclusion criteria: 1. Renal dysfunction evidenced by urine output <0.5 mL/hr/kg over the prior 24 hours 2. Serum creatinine >1.7 mg/dL 3. History of clinical seizures or EEG (Electroencephalogram) confirmed seizures 4. Concomitant treatment with another carbapenem (ertapenem or imipenem) at the time of informed consent 5. Any condition which would make the subject or the caregiver, in the opinion of the investigator, unsuitable for the study

Study Design


Intervention

Drug:
meropenem
Meropenem was administered concomitantly with compatible medications. Because an in-line filter is not appropriate due to drug binding, the 30 minute infusion was rate controlled by using appropriate infusion (syringe) pumps. Dosing and administration of other antimicrobial therapy (e.g., an aminoglycoside) was administered per local standard of care at the discretion of the infant's neonatologist. If there was a delay in the study drug shipment, sites were to use open-label meropenem to protect the safety of the participant. 20 mg/kg every 12 hours in infants <32 weeks GA and PNA < 2 weeks 20 mg/kg every 8 hours in infants <32 weeks GA and PNA = 2 weeks 20 mg/kg every 8 hours in infants =32 weeks GA and PNA < 2 weeks 30 mg/kg every 8 hours in infants =32 weeks GA and PNA = 2 weeks

Locations

Country Name City State
United States Akron Children's Hospital Akron Ohio
United States Albany Medical Center Albany New York
United States University of Michigan Ann Arbor Michigan
United States University of Alabama Birmingham Alabama
United States Suny Downstate Medical Center Brooklyn New York
United States Case Western Reserve, RB&C, UHCMC Cleveland Ohio
United States University of Texas Southwestern Medical Center Dallas Texas
United States Duke University Durham North Carolina
United States Duke University Medical Center Durham North Carolina
United States Evanston Northwestern Healthcare Evanston Illinois
United States University of Florida Gainesville Florida
United States Kapiolani Medical Center for Women and Children Honolulu Hawaii
United States Baylor College of Medicine Houston Texas
United States Indiana University - Riley Hospital for Children Indianapolis Indiana
United States Kansas City Children's Mercy Hospital Kansas City Missouri
United States University of Louisville Louisville Kentucky
United States Vanderbilt Children's Hospital Nashville Tennessee
United States Yale New Haven Hospital New Haven Connecticut
United States Children's Hospital of Oakland Oakland California
United States Children's Hospital of Orange County Orange California
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States Magee Women's Hospital Pittsburgh Pennsylvania
United States University of Utah medical Center Salt Lake City Utah
United States Sharp-Mary Birch Hospital for Women San Diego California
United States University of California Medical Center San Diego California
United States Children's National Medical Center Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
The Emmes Company, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy Success (Alive at Efficacy Visit,Last Culture (if Obtained) From Sterile Body Fluid is Negative for Bacteria (Except Staphylococcus Species) From Start of Study Drug Until Efficacy Visit,Presumptive Clinical Cure Score(PCCS) >7 at Efficacy Visit) The PCCS was derived by comparing clinical signs and symptoms prior to administration of the first dose of study drug and study Day 28.The elements of the PCCS include Mean BP,Temp,PaO2(mmHg)/FiO2,Lowest serum pH,seizures,Urine output,Cardiovascular inotrope support,C-reactive protein (CRP)and Abdominal girth.
Score - Asymptomatic to Asymptomatic 1;Asymptomatic to Worsening 0;Symptomatic to Worsening 0;Symptomatic to No change 0;Symptomatic to Improved 1;Symptomatic to Asymptomatic 1
If 7 or more of 10 signs received a score of 1, then the infant was considered a presumptive clinical cure.
GA stands for Gestational Age and PNA stands for Postnatal Age.
Average of 12 days (3 to 21 days)
Primary Deaths Up to 51 days (Recorded from the time of informed consent until 72 hours following the last dose of study drug)
Primary Meropenem Clearance Given the limited availability of blood for Pharmacokinetic (PK) assessments in this population a sparse sampling approach was utilized. Subjects were assigned to one of two Dose 1 sample collection schedules, "PK-odd" and "PK-even" based on birth date to ensure collection of PK data throughout the dose interval. In addition, PK samples were collected around approximately the 5th dose. Subjects that did not have Dose 1 PK samples could have steady-state (Dose 5) using the Dose 5 PK collection schedule. Up to 7-8hrs post drug administration
Primary Key Safety Endpoints Safety assessments included death, seizure documentation (including correlation of serum meropenem level and seizures), strictures, perforation, wound dehiscence, short gut, development of extended beta lactamase infection, development of candidiasis, antimicrobial therapy failure Up to 51 days (Adverse Events (AEs) were recorded from the time of informed consent until 72 hours following the last dose of study drug)
See also
  Status Clinical Trial Phase
Recruiting NCT05544097 - Spectral Analysis of Bowel Sounds in Preterm Babies of Less Than 32 Weeks of Amenorrhea (WA) as Predictive Factor of Enterocolitis N/A
Recruiting NCT03210831 - Early Predictors of Necrotizing Enterocolitis in Neonates
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Recruiting NCT02552706 - The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis N/A
Completed NCT02400697 - Placental Transfusion Project for Preterm Infants N/A
Completed NCT01751477 - Infloran® for Prevention of Necrotizing Enterocolitis N/A
Terminated NCT01156480 - Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants N/A
Completed NCT00787124 - Transfusions and Nitric Oxide Level in Preterm Infants
Unknown status NCT00254176 - Cysteine Supplementation in Critically Ill Neonates Phase 2/Phase 3
Recruiting NCT01441739 - Intestinal Failure in Necrotising Enterocolitis N/A
Recruiting NCT03869827 - Necrotizing Enterocolitis in Fetuses With Intrauterine Growth Restriction
Recruiting NCT04074824 - A Genome-Wide Association Study for Neonatal Diseases
Terminated NCT03320785 - Circulating Markers in Preterm Infants With Perinatal and Neonatal Inflammation
Active, not recruiting NCT03554278 - Alteration of Stool Microbiota in Preterm Infants With Anemia
Not yet recruiting NCT04541771 - The Role of Lactobacillus Reuteri in Preventing Necrotizing Enterocolitis (NEC) in Pre-term Infants Phase 2
Not yet recruiting NCT03700957 - The Impact of Docosahexaenoic Acid on the Prevention of Necrotizing Enterocolitis in Preterm Neonates N/A
Completed NCT03551600 - Splanchnic and Renal Tissue Oxygenation During Enteral Feedings in Neonates With Patent Ductus Arteriosus
Unknown status NCT01807858 - The Effects of Synbiotics on Morbidity and Mortality in Preterm Infants N/A
Completed NCT01735578 - Splanchnic Tissue Oxygenation During Enteral Feedings in Anemic Premature Infants at Risk for Necrotizing Enterocolitis N/A
Completed NCT01745510 - Enteral Administration of Docosahexaenoic Acid to Prevent Necrotizing Enterocolitis in Preterm Neonates Phase 1/Phase 2